The UK’s Medical Research Council has announced a £50 million investment to establish a new Centre of Research Excellence focused on mitochondrial genome therapeutics, in a move aimed at speeding up progress against a group of inherited disorders that currently have no cure.
Announced on 5 August 2026, the centre brings together specialists across disciplines to better understand how mutations in mitochondrial DNA cause disease and to translate that knowledge into treatments. The MRC says mitochondrial diseases affect around one in 5,000 people and can lead to severe disability, progressive decline and premature death.
A research programme built around an urgent unmet need
According to the MRC, the new centre will also examine how mitochondrial DNA mutations are linked beyond inherited conditions, including neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration. The organisation said the work is intended to create the scientific foundations for entirely new therapeutic strategies.
Project lead Professor Michal Minczuk of the University of Cambridge said the centre will provide “pioneering approaches” to understanding and treating diseases caused by mitochondrial genome mutations. He added that the long-term UK platform is designed to give the country the scale, expertise and infrastructure needed to position it as a global leader in mitochondrial genome therapeutics.
International partnerships and patient involvement
The centre will be led by the University of Cambridge and will partner with the University of Birmingham, The University of Manchester, Heidelberg University, the University of Queensland and the Imagine Institute in Paris. It will also work with the Lily Foundation and industry partners worldwide.
Dr Ceri Williams, Executive Director of Challenge Led Themes at MRC, said the UK has been at the helm of mitochondrial science and that the new centre builds on that foundation to make progress on the root causes of mtDNA mutations. She said the interdisciplinary approach has the potential to improve prevention, detection and treatment, while protecting families affected by the disease.
What the funding could mean for patients
The announcement comes as researchers continue to look for better ways to address rare but devastating conditions that place a heavy burden on patients and families. The MRC said the centre’s work will harness emerging technologies to engineer the mitochondrial genome and develop advanced models of common pathogenic mtDNA mutations.
Liz Curtis, chief executive officer and founder of the Lily Foundation, said the initiative could transform understanding of mitochondrial disease and that embedding patient perspectives from the outset will help ensure family priorities shape the research agenda. For UK science, the investment is also a signal that mitochondrial research remains a strategic area with potential implications well beyond a single disease group.
Separately, Nature highlighted a recent study suggesting the recombinant shingles vaccine may be linked to a lower risk of cardiovascular problems, illustrating how medical research continues to uncover unexpected connections between prevention and broader health outcomes.
Photo source: AI-generated or edited image
